OUR EXPERTISE
Proven Global Experience Across Pharma Including Top 10 Industry Leaders
Trusted Global Partnerships
Broad Therapeutic Coverage
Multi-Audience Communication
Execution-Ready Delivery
Experience spanning the world’s top 20 therapeutic areas
From ICU sedation to operating-theatre IV and inhalational induction and maintenance , our work spans the full spectrum of anaesthesia. We have developed comprehensive materials across key products, including propofol, remifentanil, sufentanil, sevoflurane and dexmedetomidine. This includes in-depth scientific content, updates on emerging topics in anaesthesia, high-visibility touchpoints for ICU and theatre redlines, and concise pocket dosing guides — all designed to support anaesthesiologists in enhancing clinical knowledge and strengthening brand engagement.
In an era defined by rising antibiotic resistance and the spread of multidrug-resistant pathogens, we have partnered with microbiology, physician, GP, and pharmacy audiences across both hospital and community settings. Our work spans the full spectrum of anti-infective therapeutics—supporting products for severe, life-threatening infections such as ertapenem, imipenem, vancomycin, ceftriaxone, and caspofungin, as well as those widely used in community care, including amoxicillin-clavulanic acid, fluconazole, and amorolfine.
We develop comprehensive scientific materials and targeted campaigns focused on antimicrobial stewardship, empowering healthcare professionals and institutions to use antibiotics responsibly—ensuring the right drug, at the right dose, for the right patient and indication
On the antiviral spectrum we have worked extensively in Hepatitis B ( tenofivir alofenamide) and Hepatitis C (sofosvubir/velpatasvir) promoting awareness of curative treatment, identifying treatment gaps and vulnerable populations. Our team has developed impactful community education initiatives and targeted physician campaigns that support national and global efforts to eliminate Hepatitis C, in alignment with the WHO’s 2030 eradication goal. For our HIV work, please view HIV
With asthma a serious global problem,particularly rising in the pediatric population with an estimated 22 million children affected and over 12,000 annual deaths, asthma control remains a key therapeutic area. We have worked extensively across the therapeutic spectrum on dual and triple inhaler therapies such as salmeterol/fluticasone propionate, fluticasone furoate/vilanterol, as well as leukotriene antagonists such as montelukast, and corticosteroids. Our team has developed many educational tools for asthma awareness and control, checklists, digital monitoring tools and physician communications material. We have also worked to develop specialist training modules and continuing educational programs.
From the first blockbuster biologic adalimumab HUMIRA to the subsequent biological advances and therapeutics in rheumatoid arthritis, Crohn’s and IBD, Psoriatic arthritis and Psoriasis, we have covered them all. Working closely with regulatory departments, brand managers, case managers and physician-associations to bring these brands to market, we have produced communication material across the spectrum including patient support programs, screening for biologics programs, market access documents, KOL advisory board scientific support, congress material, physician visual aids, videos demonstrating how the patients can self inject, patient testimonials and much more. We have witnessed how these products have revolutionized the therapeutic landscape of autoimmune disease and worked with brands from launch to maturity.
When biosimilars hit the market, we were front and center in educating the specialists on biosimilars, how they differ from genetics and show the clinical evidence comparing the biosimilar to the originator. In many markets biosimilars with established efficacy and safety versus originators, were a game changer as their lower price meant greater accessibility for more patients and payors were more likely to fund biosimilars as the evidence base grew stronger. We supported companies launching biosimilars in the autoimmune space by creating prelaunch educational campaigns and thought leadership materials so that by the time the product hit the market, acceptance was high.
Cardiovascular disease is the no 1 killer of men and women worldwide. We have worked in multiple therapeutic areas in CVD, from CVD prevention campaigns on lifestyle management to primary care physician education on the differences in pathophysiology, disease presentation and management between men and women. We have also worked on various therapeutics from the launch of NOACs ( novel oral anticoagulants) such as rivoroxaban, to extremely specialised products such as intravenous thrombolysis for example altoplase, used in cardiac cath labs by interventional cardiologists.
COPD is a significant public health challenge, and a leading cause of chronic morbidity and mortality worldwide. On a global scale, the burden of COPD is expected to rise in the coming decades due to ongoing exposure to risk factors and the aging population. We have worked extensively in COPD from manuscripts, patient education, guideline recommendation educational pieces, to treatment options, including new once daily triple therapy inhaler treatments such as fluticasone furoate/umeclidinium/vilanterol.
Our experience in the dermatology arena spans over two decades working with Dermatology focused pharmaceutical companies who work across acne, psoriasis, atopic dermatitis, rosacea and actinic keratosis. We have been active in key opinion expert guideline development for atopic dermatitis, corticosteroid creams, and biologic therapy for psoriasis and therapeutics for rosacea and AK. We have also been alongside our clients for the launch and continual education of non-corticosteroid cream options for AD, such as pimecrolimus. Our acne portfolio includes work on acne education particularly around understanding acne and the importance of compliance, dermatologist educational material and product marketing of new classes of topical retinoids such as trifarotene, to new fixed dose combination topical therapies adapalene/benzyl peroxide as well as antibiotics and hormonal contraceptives.
Our experience in Type 2 diabetes spans from the educational to the extremely specialized. Working with pharma companies with large diabetes and metabolic syndrome portfolios we have created educational content for diabetic patients. We also work in specialized areas such as unique stem cell technology for diabetic foot ulcer (DFU) and in diabetic retinopathy and anti vascular endothelial growth factor (VEGF) therapy for Diabetic Macular Edema.
Our major pharma work in hematology focuses on iron deficiency anemia and the role of oral and IV iron. We work on patient educational material for websites, patient information leaflets to increase disease awareness of iron deficiency and the at risk populations.
Our major work in haematooncology includes developing specialist material for hematologists spanning leukemia, lymphoma and multiple myeloma to name a few.Our major work in diagnosis is in fully digital microscopy and morphology in the peripheral blood smear and bone marrow aspirates in the hematology laboratory environment.
Working in South Africa, the leading experts in HIV management , we cover the full range of first, second and third line treatment options. We have supported clients through the emergence of new classes of HIV treatment such as dolutegravir, inSTI as well as combination therapies o NNRTs or Protease inhibitors (PIs) as well as assisting physicians with tools to support personalized patient treatment choices, taking into account age and comorbidities.
Our work on pembrolizumab, a blockbuster PD-L1 inhibitor indicated in multiple tumor types in both monotherapy and combination therapy, has spanned a decade. Indicated in 18 different tumor types including melanoma, no-small cell lung cancer ( NSCLC), head & neck, bladder, gastric, esophageal, cervical, renal, hepatic,, triple negative breast cancer, ovarian and cervical cancer as well as mismatch repair or microsatellite instability (MSI-H/dMMR) cancers. This therapeutic has changed the oncology landscape offering unprecedented overall survival and disease-free survival rates, whilst improving cancer patients quality of life.
Our expertise in Infectious disease spans from ICU bacterial and fungal infections working with IV antibiotics such as imipenem, ertapenem,vancomycin, caspofungin, as well as educational material for hospitals and ICUs on how to create antimicrobial stewardship programs. In line with WHO Goal of Hepatitis C eradication by 2030 we have worked on identification of key high risk groups for Hep C infection as well as treatments such as sofosbuvir/velpatasvir. Our work also spans educational and treatment options for Hepatitis B, and malaria, as well as respiratory infections, community and hospital-acquired pneumonia, influenza, and respiratory syncytial virus.
From common to rare, our work spans hypothyroidism, hypoparathyroidism to a rare chronic endocrine disorder caused by hypersecretion of growth hormone. Working with the arena of thyroid hormone replacement, subclinical hypothyroidism, managing patients on a narrow therapeutic index drug in hypothyroidism to the intricate management of patients with acromegaly with the use of somatostatin analogues and early identification to mitigate the risk of multiple associated comorbidities such as hypertension,and diabetes leading to morbidity and mortality.
In the mental health space we have marketed all classes of anxiolytics and antidepressants from older selective serotonin reuptake inhibitors ( SSRIs) to noradrenaline dopamine inhibitors ( NDRIs), serotonin noradrenaline reuptake inhibitors (SNRIs) atypical antidepressants such as agomelatine. We have worked at the specialist, primary care and patient level on educational programs, screening checklists and disease awareness. Our work also extends to atypical antipsychotics and antiepileptics in schizophrenia and bipolar disorder.
We have worked extensively in Attention Deficit Hyperactivity Disorder on multiple therapeutics (including long acting stimulants, atomoxetine and lisdexamphetamine, as well as producing extensive disease educational material in both the adult and pediatric market. Migraine and other types of headache is also a key therapeutic area where we have a wealth of experience. We enjoy our work on specialist brands for Parkinson's Disease and Multiple Sclerosis as well as Restless Leg Syndrome.
We have extensive oncology expertise across a range of tumor types and a range of key oncology products, in early and advanced stages of melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial, head and neck, ovarian, breast and cervical cancer, multiple myeloma, acute and chronic lymphocytic leukemia, non-Hodgkins lymphoma, and many more.. We have also worked on other rarer cancer types such as neuroendocrine tumors (NETS) . To learn more about our expertise, book a meeting.
Our most recent work in Ophthalmology involves working with Science Corporation on their subretinal neurostimulation implant and their clinical development of manuscripts for publication, with the most recent manuscript published in NEJM. Other work in ophthalmology includes working on anti-VEGF inhibitors such as ranibizumab and brolucizumab for diabetic macular edema at specialist level.
Our work in obesity includes multiple educational elements for metabolic syndrome risk screening and identification. We also work in the nonpharmacological therapeutic arena of obesity management on the scientific publication of the clinical studies of Epitomee a novel oral self administered medical device for weight management consisting of a hydrogel that self-expands in the stomach to increase satiety and produce weight loss with a favorable safety profile.
Our pain portfolio spans the over the counter pharmaceutical products predominantly ibuprofen, through to palliative cancer pain products. We have done numerous and extensive training manuals on the pathophysiology of pain, the place of different product classes in acute and chronic pain management. We have also worked extensively in neuropathic pain, with products such as pregabalin, as well as promoting the therapeutic approach to this difficult condition.
Our work in rheumatology spanning educational elements and therapeutic products includes rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Over the years we have worked with various biologics to bring additional treatment options to patients suffering from these debilitating autoimmune diseases and have worked extensively on early aggressive approaches, treat-to-target to reduce disease progression and joint damage.
Vaccines, widely considered a “preventative miracle” and the single most effective public health intervention in history, have saved millions of lives over the past 50 years. Despite the efficacy , we have witnessed the current challenge of vaccine hesitancy, vaccine refusal and outbreaks of vaccine-preventable diseases that could be eradicated. We have worked across the spectrum of diphtheria, pertussis, tetanus, measles, mumps, rubella,varicella, rotavirus, flu hepatitis A and B, and COVID vaccines.